StreetInsider.com News Articles

Kepler Cheuvreux Upgrades Essity AB (ESSITYB:SS) (ESSYY) to Buy

Thu, 03 Sep 2026 04:57:37 -0400

Kepler Cheuvreux analyst Karel Zoete upgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Hold to Buy with a price target of SEK320.00 (from SEK265.00).

Kepler Cheuvreux Upgrades Essity AB (ESSITYB:SS) (ESSYY) to Buy

Thu, 03 Sep 2026 04:57:37 -0400

Kepler Cheuvreux analyst Karel Zoete upgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Hold to Buy with a price target of SEK320.00 (from SEK265.00).

Kepler Cheuvreux Upgrades Essity AB (ESSITYB:SS) (ESSYY) to Buy

Thu, 03 Sep 2026 04:57:37 -0400

Kepler Cheuvreux analyst Karel Zoete upgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Hold to Buy with a price target of SEK320.00 (from SEK265.00).

Kepler Cheuvreux Upgrades Essity AB (ESSITYB:SS) (ESSYY) to Buy

Thu, 03 Sep 2026 04:57:37 -0400

Kepler Cheuvreux analyst Karel Zoete upgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Hold to Buy with a price target of SEK320.00 (from SEK265.00).

Kepler Cheuvreux Upgrades Essity AB (ESSITYB:SS) (ESSYY) to Buy

Thu, 03 Sep 2026 04:57:37 -0400

Kepler Cheuvreux analyst Karel Zoete upgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Hold to Buy with a price target of SEK320.00 (from SEK265.00).

Kepler Cheuvreux Upgrades Essity AB (ESSITYB:SS) (ESSYY) to Buy

Thu, 03 Sep 2026 04:57:37 -0400

Kepler Cheuvreux analyst Karel Zoete upgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Hold to Buy with a price target of SEK320.00 (from SEK265.00).

UBS Double Downgrades Essity AB (ESSITYB:SS) (ESSYY) to Sell

Thu, 03 Sep 2026 03:39:34 -0400

UBS analyst Andrei Condrea downgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Buy to Sell with a price target of SEK235.00 (from SEK280.00).

The analyst comments: “We expect downside risk as Essity enters a new cost inflation cycle: (i) organic sales growth is likely to undershoot consensus in H2 and 2027, remaining below the group's >3% medium-term target; (ii) EBITA faces pressure from rising raw material costs, with consensus underestimating both inflation headwinds and limited pricing recovery; and (iii) a potential Consumer Tissue exit could prove more complex than the market might assume.

We forecast 2027 organic sales growth of 2.6% (vs consensus

UBS Double Downgrades Essity AB (ESSITYB:SS) (ESSYY) to Sell

Thu, 03 Sep 2026 03:39:34 -0400

UBS analyst Andrei Condrea downgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Buy to Sell with a price target of SEK235.00 (from SEK280.00).

We forecast 2027 organic sales growth of 2.6% (vs consensus

UBS Double Downgrades Essity AB (ESSITYB:SS) (ESSYY) to Sell

Thu, 03 Sep 2026 03:39:34 -0400

UBS analyst Andrei Condrea downgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Buy to Sell with a price target of SEK235.00 (from SEK280.00).

We forecast 2027 organic sales growth of 2.6% (vs consensus

UBS Double Downgrades Essity AB (ESSITYB:SS) (ESSYY) to Sell

Thu, 03 Sep 2026 03:39:34 -0400

UBS analyst Andrei Condrea downgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Buy to Sell with a price target of SEK235.00 (from SEK280.00).

We forecast 2027 organic sales growth of 2.6% (vs consensus

UBS Double Downgrades Essity AB (ESSITYB:SS) (ESSYY) to Sell

Thu, 03 Sep 2026 03:39:34 -0400

UBS analyst Andrei Condrea downgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Buy to Sell with a price target of SEK235.00 (from SEK280.00).

We forecast 2027 organic sales growth of 2.6% (vs consensus

UBS Double Downgrades Essity AB (ESSITYB:SS) (ESSYY) to Sell

Thu, 03 Sep 2026 03:39:34 -0400

UBS analyst Andrei Condrea downgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Buy to Sell with a price target of SEK235.00 (from SEK280.00).

We forecast 2027 organic sales growth of 2.6% (vs consensus

Essity AB (ESSITYB:SS) (ESSYY) PT Raised to SEK240 at Deutsche Bank

Wed, 26 Aug 2026 03:08:54 -0400

Deutsche Bank analyst Tom Skykes raised the price target on Essity AB (ESSITYB:SS) (OTC: ESSYY) to SEK240.00 (from SEK230.00) while maintaining a Sell rating.

The analyst comments: “Essity may or may not see a negative impact from a US/Canada trade war (previously higher import tariffs into Canada were a 60bps headwind to Group gross margin). However, we don't model this into our forecasts currently. We make some small changes to our below consensus earnings post the H1 results and remain ~3% below the market on 27e EPS. Essity now trades on ~15x fwd 12m PE and is at trend PE relative

Essity AB (ESSITYB:SS) (ESSYY) PT Raised to SEK240 at Deutsche Bank

Wed, 26 Aug 2026 03:08:54 -0400

Deutsche Bank analyst Tom Skykes raised the price target on Essity AB (ESSITYB:SS) (OTC: ESSYY) to SEK240.00 (from SEK230.00) while maintaining a Sell rating.

Essity AB (ESSITYB:SS) (ESSYY) PT Raised to SEK240 at Deutsche Bank

Wed, 26 Aug 2026 03:08:54 -0400

Deutsche Bank analyst Tom Skykes raised the price target on Essity AB (ESSITYB:SS) (OTC: ESSYY) to SEK240.00 (from SEK230.00) while maintaining a Sell rating.

Essity AB (ESSITYB:SS) (ESSYY) PT Raised to SEK240 at Deutsche Bank

Wed, 26 Aug 2026 03:08:54 -0400

Deutsche Bank analyst Tom Skykes raised the price target on Essity AB (ESSITYB:SS) (OTC: ESSYY) to SEK240.00 (from SEK230.00) while maintaining a Sell rating.

Essity AB (ESSITYB:SS) (ESSYY) PT Raised to SEK240 at Deutsche Bank

Wed, 26 Aug 2026 03:08:54 -0400

Deutsche Bank analyst Tom Skykes raised the price target on Essity AB (ESSITYB:SS) (OTC: ESSYY) to SEK240.00 (from SEK230.00) while maintaining a Sell rating.

Essity AB (ESSITYB:SS) (ESSYY) PT Raised to SEK240 at Deutsche Bank

Wed, 26 Aug 2026 03:08:54 -0400

Deutsche Bank analyst Tom Skykes raised the price target on Essity AB (ESSITYB:SS) (OTC: ESSYY) to SEK240.00 (from SEK230.00) while maintaining a Sell rating.

Goldman Sachs Downgrades Essity AB (ESSITYB:SS) (ESSYY) to Sell

Tue, 28 Jul 2026 03:06:20 -0400

Goldman Sachs analyst Aron Adamski downgraded Essity AB (ESSITYB:SS) (OTC: ESSYY) from Neutral to Sell with a price target of SEK255.00 (from SEK270.00).

The analyst comments: “We downgrade Essity to Sell from Neutral with a SEK 255 price target (9% downside). We see scope for consensus downgrades as pricing continues to lag accelerating input-cost inflation. While a Consumer Tissue divestment could act as a catalyst, the earnings impact remains too uncertain to assess at this stage, constraining near-term upside.